![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bruker Corporation | NASDAQ:BRKR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
1.98 | 3.12% | 65.39 | 65.35 | 65.44 | 65.80 | 63.0101 | 63.89 | 299,395 | 19:04:59 |
Bruker (NASDAQ: BRKR) today announced five orders for ultra-high field (UHF) nuclear magnetic resonance (NMR) spectroscopy systems from Europe and Brazil in recent months. These UHF systems have been funded for cutting-edge NMR research in structural biology, intrinsically disordered proteins (IDPs), membrane proteins, macro-molecular complexes and interactions, cell biology, disease research, as well as in advanced materials research.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150917005142/en/
Next generation Aeon 1.2 GHz NMR system (Photo: Business Wire).
Bruker defines UHF as NMR systems with 1H proton frequency of 900 MHz or above. Other high-field 700, 800 and 850 MHz orders are not included in the UHF definition. The recent UHF NMR orders include three 900 and 950 MHz systems from Brazil, Switzerland and the UK, with revenue typically within 18 months from order:
In 2015, Bruker also has received two additional orders for next-generation GHz-class systems from France and Germany, and Bruker’s backlog for GHz-class NMR systems has now increased to nine (9) systems for different European and Canadian customers. Bruker expects to begin to recognize revenues from next-generation Aeon™ 1.0 GHz systems in 2016. The Aeon 1.2 GHz systems backlog is projected to ship over several years, starting in late 2017 or 2018. Revenue timing for future 1.2 GHz systems has inherent risks, and depends on further progress in high-temperature superconductor (HTS) materials and HTS-based NMR magnet technology.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements reflect the views of management at the time such statements are made and are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations. These statements include our expectations related to the production and delivery of technologically advanced UHF NMR systems and the amount and timing of future revenues from UHF NMR systems orders currently in our backlog. Although we believe the assumptions upon which these forward-looking statements are based are reasonable, any of these assumptions could prove to be inaccurate and the forward-looking statements based on these assumptions could be incorrect. Our actual future performance may differ materially from such expectations as a result of important risk factors, which include, in addition to those identified in the our Annual Report on Form 10-K for the year ended December 31, 2014 and our other subsequent filings with the Securities and Exchange Commission, risks and uncertainties associated with our ability to develop high-temperature superconductor (HTS) materials and HTS-based magnets required for 1.2 GHz NMR systems. These risks and uncertainties could cause actual results to differ materially from those stated or implied in these forward-looking statements. We expressly disclaim any obligation to update or revise these forward-looking statements, except as required by law or regulation.
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
For more information on Bruker, please visit www.bruker.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20150917005142/en/
Bruker CorporationMedia Contact:Dr. Thorsten Thiel, +49 (721) 5161–6500Director of Marketing Communicationsthorsten.thiel@bruker.comorInvestor Contact:Joshua Young, +1-978-663-3660, ext. 1479VP, Investor Relations & Corporate Developmentjoshua.young@bruker.com
1 Year Bruker Chart |
1 Month Bruker Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions